Douglas A. Hamilton

The Group's principal activity is to develop new drug and improve formulations of existing drug that target current unmet and underserved medical need primarily in the pain management market. It develops simple and user-friendly products, including new modes and routes of delivery for drugs optimized for relieving moderate-to-severe pain. The Group is in the development stage.

IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS’s product candidates address the market segment for prescription medications focused on treating acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain and trauma. The product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments.

S.E.A. Medical Systems, Inc. develops medical devices that catch serious or life-threatening intravenous drug errors. It specializes in developing medical devices that catch serious or life-threatening intravenous drug errors before they harm patients. It has created a disruptive platform technology with life-saving product applications, allowing for the identification and characterization of medical solutions in real time. The firm offers IV Check that validates IV preparations and measures pharmacy returns to detect narcotic or scheduled drug diversion. The company was founded in October 2008 by James W. Bennett, Leo Matsiev and Michael J. Weickert and is headquartered in Emerald Hills, CA.

Part of Swedish Orphan Biovitrum AB, PolaRx Biopharmaceuticals is a company that manufactures TriOxide drugs for the treatment of leukemia and other cancers. The company is based in New York, NY. The company was founded by Fred H. Mermelstein, Peter Morgan Kash, Raymond P. Warrell. PolaRx Biopharmaceuticals was acquired by CTI BioPharma Corp., part of Swedish Orphan Biovitrum AB from June 27, 2023 on January 13, 2000 for $17.50 million.

Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.